Edition:
United States

Novo Nordisk A/S (NVO)

NVO on New York Consolidated

37.41USD
26 Apr 2017
Change (% chg)

$0.33 (+0.89%)
Prev Close
$37.08
Open
$37.30
Day's High
$37.53
Day's Low
$37.27
Volume
1,840,854
Avg. Vol
2,375,294
52-wk High
$57.44
52-wk Low
$30.89

Select another date:

Fri, Apr 21 2017

BRIEF-Xoma receieves notice to terminate license agreement from Novo Nordisk

* Xoma -on april 20, 2017 co received notice from Novo Nordisk a/s, relating to termination of exclusive license agreement with co due to strategic and business reasons

BRIEF-Novo's once-weekly semaglutide shows consistent bloodglucose reductions

* Says once-weekly semaglutide demonstrated consistent bloodglucose reductions and weight loss regardless of background oral antidiabetic treatment

BRIEF-Novo Nordisk resubmits new drug application for fast-acting insulin aspart in the U.S

* Says has resubmitted the new drug application (NDA) for fast-acting insulin aspart as a class II re-submission to the United States Food and Drug Administration (FDA)

BRIEF-Novo Nordisk launches Fiasp-drug in Canada

* Says Fiasp, a new, fast-acting mealtime insulin for the treatmentof diabetes in adults, has been launched in Canada on Monday Further company coverage: (Reporting by Stine Jacobsen)

EMA panel backs Novo Nordisk's hemophilia B drug

A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's hemophilia B drug.

UPDATE 1-EMA panel backs Novo Nordisk's haemophilia B drug

March 24 A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's haemophilia B drug.

EMA panel backs Novo Nordisk's haemophilia B drug

March 24 A panel of the European Medicines Agency said it recommended granting marketing approval to Danish drugmaker Novo Nordisk's haemophilia B drug.

BRIEF-EU recommends approval of Novo Nordisk's haemophilia drug

* Recommends approval of Novo Nordisk's Nonacog Beta Pegol drug for treatment of haemophilia

BRIEF-Novo Nordisk gets positive opinion for label update in EU for Tresiba

* The Committee for Medicinal Products for Human Use (CHMP), under the European Medicines Agency (EMA), has issued a positive opinion, recommending an update of the label for Tresiba (insulin degludec) to include data from the SWITCH 1 and 2 clinical trials

BRIEF-Denmark's Novo Nordisk will not turn into big M&A machine-CEO

March 23 The CEO of Novo Nordisk's, the world's biggest diabetes company, made the following comments at the firm's annual general meeting on Thursday:

Select another date:

More From Around the Web